Publishing options: Couperin associated corresponding authors
## 1. Key definitions

<table>
<thead>
<tr>
<th>Terminology</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submitting corresponding author</td>
<td>Submitting corresponding author is the author who submits the article to Elsevier and stays in contact with Elsevier in the end-to-end journey.</td>
</tr>
<tr>
<td></td>
<td>This is the author who makes the publishing choice on behalf of the author group.</td>
</tr>
<tr>
<td></td>
<td>Every article has one corresponding author.</td>
</tr>
<tr>
<td>Acceptance Date</td>
<td>This is the date the journal accepts the article for publication.</td>
</tr>
<tr>
<td>Elsevier OA Platform</td>
<td>Elsevier OA Platform (EOAP) is a user-friendly interface where we present the institutional administrators with the open access articles eligible for the agreement.</td>
</tr>
<tr>
<td></td>
<td>Administrators at the institution validate the eligibility of the author for an OA agreement.</td>
</tr>
<tr>
<td>Gold Open Access</td>
<td>The final version of the published journal article is made freely available, immediately, to everyone. An author can publish Gold Open Access in an open access journal OR in a Hybrid journal which offers open access.</td>
</tr>
</tbody>
</table>
## 2. Eligibility criteria

<table>
<thead>
<tr>
<th>Eligibility component</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceptance date</td>
<td>The acceptance date of the article should fall within the period of agreement for your institution</td>
</tr>
<tr>
<td>Author affiliation</td>
<td>The submitting corresponding author must be affiliated with a participating institution in the agreement.</td>
</tr>
<tr>
<td>Journal title</td>
<td>The article must be submitted to and accepted in a participating journal.</td>
</tr>
<tr>
<td>APC available</td>
<td>Institution has APCs for the year</td>
</tr>
</tbody>
</table>
## 3. Agreement Overview

<table>
<thead>
<tr>
<th>Journal Bucket</th>
<th>Agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Core Hybrid/ Core Gold</td>
<td>The eligible submitting corresponding authors receive full APC coverage upon validation in EOAP. All institutions have a quota of 11138/11268/11410/11566 for 2024-2027</td>
</tr>
<tr>
<td>Cell Press/Lancet Hybrid &amp; Gold</td>
<td>The eligible submitting corresponding authors receive 10% discount upon validation in EOAP</td>
</tr>
</tbody>
</table>
Publishing options at submission (Editorial Manager)
As part of the submission journey, once the author uploads the manuscript files, corresponding author provides the affiliation details.
Corresponding author also provides the research funder details if applicable. Clicking on ‘Build PDF for Approval’ will take them to the next page.

The author only needs to provide the affiliation and funder details once as we will copy this into the post acceptance journey.
System presents information about the publishing options and informs that the choice the author makes at submissions is an indication.

Please indicate your Publishing Options

This is a hybrid journal. The journal publishes both subscription and OA articles. We will present your personalized Publishing Options based on the Institution and Funding details you have given us. Please note that at this stage in your submission, you are only indicating your preference. We will ask you to make a final choice after the journal has accepted your manuscript.

Publishing Options

Cancel Proceed
Publishing options in a Hybrid journal

Gold Open Access

- Publish as an Open Access article

Make my final published article available to everyone upon acceptance.

I am an author affiliated with the Nantes University. As there is an agreement in place between the French higher education and research institutions consortium (Couperin) and Elsevier to cover the APC (Article Publishing Charge) for publishing Open Access, I do not have to pay an APC if all of the following criteria are met:

- My institution has APCs available by the time the journal accepts the article.
- My institution approves using the agreement funds to pay the APC.

To pay on acceptance

- Only applicable if article accepted

<table>
<thead>
<tr>
<th>APC</th>
<th>EUR 3,120.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Institutional Agreement Discount</td>
<td>- 3,120.00</td>
</tr>
<tr>
<td>To pay (on validation)</td>
<td>0.00</td>
</tr>
</tbody>
</table>

Subscription

- Publish as a subscription article

I will publish my article subscription, making my final published article immediately available to journal subscribers, and to other groups as part of Elsevier’s programs.

I understand I can immediately share my article within my institution and privately with collaborators, and share my accepted manuscript publicly in my institution’s repository after 12 months. I have additional article sharing rights outlined here.
Publishing in Cell Press/Lancet (APC discount)

- Authors are informed that they would need to provide a PO (being implemented)
Publishing options after acceptance
Corresponding author receives an email post acceptance with a unique link to complete the author journey and choose publishing options.

Author clicks on Complete the Rights and Access information form.
Corresponding author selects his/her affiliation details which we use to identify the authors and match them to the Couperin Elsevier agreement.

Please note that the author has already provided this information at submission; it is prepopulated.
Corresponding author also adds the co-author affiliation details

Were there any co-authors for this article?
- Yes
- No

Add Co-author Details

Please provide details for all co-authors. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

*Hint: start the organization search using the main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you’re unable to find the specific department, then selecting the main organization is sufficient. For more tips on searching for an organization please visit our Support Center.

First name or Initial*
John

Last name*
Head

Organization name*
KU Leuven

Or use recently selected organization

+ Add another co-author
Author can add the Funder details. Funder can be the affiliated institution or a different one. In this case it is Milliman.
Based on the affiliation details, the author sees the Publishing Options. Gold OA option is followed by Subscription option, and we inform the author that agreement covers the APC.

If the librarian/admin at the institution rejects the author request in the Elsevier Platform, we also make it clear that the authors will receive a full price invoice.

Author selects Gold OA.
Publishing in **Cell Press/ Lancet** (APC discount)

- Authors are informed that they would need to provide a PO (being implemented)
- System presents the author with the CC license options
- CC BY is pre-selected
Author selects the rights

Select Your Status

- I am the sole author of the manuscript
- I am one author signing on behalf of all co-authors of the manuscript

Please indicate which of the below applies to you:

- We are all US Government employees and the Article is public domain and therefore the 'License of publishing rights' clause does not apply
- I am a US Government employee but some of my co-authors are not
- I am not a US Government employee but some of my co-authors are
- The work was performed by contractors of the US Government under contract number:

Contract Number:

- All or some of the authors are UK, Canadian or Australian Government employees and Crown Copyright is asserted
- Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted
- None of the above
- I am signing as an authorized representative and on behalf of my employer

Signed on Behalf of Corresponding Author

Please complete this section if you are not the corresponding author as listed above. A copy of the agreement will be sent to you and the corresponding author.

- I am signing on behalf of the corresponding author

Name, job title and company (if employer representative):

E-mail address:
System presents author with the Journal License Publishing Agreement

The non-exclusive license agreement for the CC BY license

Elsevier B.V.

Your Status

- I am one author signing on behalf of all co-authors of the manuscript

License of Publishing Rights

I hereby grant Elsevier B.V. an irrevocable non-exclusive license to publish, distribute and otherwise use all or any part of the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in all forms and media (whether now known or later developed) in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication.

I acknowledge the importance of the integrity, authenticity and permanence of the scholarly record and agree that the version of the Article that appears or will appear in the journal and embodies all value-adding publisher activities (including peer review co-ordination, copy-editing, formatting, (if relevant) pagination, and online enrichment) shall be the definitive final record of published research ("the Published Journal Article").

I further acknowledge and agree that nothing in this Agreement shall be deemed to permit redundant/duplicate publication of the Article in violation of publishing ethics principles, as further described below.

Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.
Author agrees to the Journal License Publishing Agreement

Author representations

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses which conflict with the terms of this License Agreement.
- If I and/or any of my co-authors reside in Russia, Belarus, Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See https://www.elsevier.com/about/our-business/policies/patient-consent for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier B.V. ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher’s copyright and access policies, please see http://www.elsevier.com/copyright.

I have read and agree to the terms of the License Agreement.

9 February 2024
Once the author clicks on Finish:

- Corresponding author and coauthors receive a copy of summary via email

- Article becomes OA on ScienceDirect within 24 hours

- Librarian/admin at the institution will receive a notification for validation within 48 hours who then has 3 weeks to validate the request

- If the Librarian/admin approves the request, the author will receive the full APC coverage

- If the Librarian/admin rejects the request, the author will have a choice to pay or publish subscription free of charge
Support for authors and librarians/administrators

- For Authors— oasupport@elsevier.com

- For Librarians/Administrators, related to activating or modifying EOAP—agreementactivation@elsevier.com

- APC Couperin Team: apc@couperin.org

Links
Hub client Couperin (elsevier.com)
Elsevier < Couperin
Find a journal | Journal Finder (elsevier.com)